LLS Targets Four Areas for Research
The Leukemia and Lymphoma Society hones in on four critical areas to be researched:
"The Leukemia & Lymphoma Society (LLS) is taking an aggressive approach to tackling the challenge of improving outcomes for patients with cancers that remain stubbornly resistant to treatment. As it has for more than 62 years, LLS will continue to accept applications from the world's best and brightest scientists to advance progress in all areas of blood cancer, and award grants based on merit. In addition LLS has identified four specific areas of need, and is soliciting applications from scientists and physicians who are working on these difficult problems.
"We are charting the course by identifying and prioritizing the areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particular diseases," said Louis DeGennaro, Ph.D., LLS chief mission officer. "LLS wants to deliver better treatments, faster, to patients, and we have developed an innovative, strategic approach to achieve this goal.""
Read More: http://www.medilexicon.com/medicalnews.php?newsid=211513
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
